iPSC Joint Committee (JSRM-ISCT)

Aims & Scope

The objective of the committee is to drive the clinical translation of cell and gene therapies worldwide by engaging leaders and actors in the iPSC field to promote safe and effective iPSC-based therapies. The committee will seek to address some of the pre-clinical efficacy and safety issues at the core of iPSC translation, and provide a platform to discuss clinical testing, technologies, and the manufacturing of iPSC-based therapies.

• Assist in the planning of the Annual Meeting scientific program and the review of submitted abstracts in the iPSC field
• Review the status of the iPSC field and compile position papers on the relevant scientific issues that must be addressed to advance or enable cellular therapies utilizing iPSCs
• Develop educational resources and engage in scientific discourse as necessary to advance the field

The iPSC Committee is jointly organized with the Japanese Society for Regenerative Medicine.

Selected Publications

• Considerations for the development of iPSC-derived cell therapies: A review of key challenges by the JSRM-ISCT iPSC Committee (2024)
  
  

The Committee

Co-Chair

Shin Kawamata, MD, PhD
November 2021–Present

Cyto-Facto
Kobe, Japan

Co-Chair

Shin Kaneko, MD, PhD
November 2021–Present

Kyoto University
Kyoto, Japan

Members:

Hiroto Bando, PhD, MBA
Minaris Regenerative Medicine
Kanagawa, Japan

Wanxing Cui, MD, PhD
Georgetown University Hospital
Washington, United States

Kouichi Hasegawa, PhD
CUORiPS Inc.
Osaka, Japan

Tetsuji Hayashi, MEng
Alloy Therapeutics
Kanagawa, Japan

Ji Hyeon Ju, MD, PhD
Catholic University of Korea
Seoul, Korea

Takehiko Kaneko, MD
Heartseed Inc.
Tokyo, Japan

Michael Kuo, MT (ASCP)
Vita Therapeutics
Rockville, United States

Uma Lakshmipathy, PhD
Thermo Fisher Scientific
Carlsbad, Unites States

Marinna Madrid, PhD
Cellino
Cambridge, Unites States

Eiki Maeda, PhD
Shinobi Therapeutics
Kanagawa, Japan

Akio Narukawa, MS
VC Cell Therapy Inc.
Kobe, Japan

Martin Maiers, MSc
NMDP
Minneapolis, United States

Bruno Marques, PhD
Century Therapeutics
Philadelphia, United States

Ross Meyers, PhD
University of Wisconsin
Madison, United States

Jo Mountford, PhD
Scottish National Blood Transfusion Service
Edinburgh, United Kingdom

Lise Munsie, PhD
BlueRock Therapeutics
Toronto, Canada

George Muschler, MD
Cleveland Clinic
Cleveland, United States

Yoji Sato, PhD
National Institute of Health Sciences
Kanagawa, Japan

Stephen Sullivan, PhD, MBA, FRSM
Lindville Bio
Edinburgh, United Kingdom

Jun Takahashi, MD, PhD
Kyoto University
Kyoto, Japan

Anthony Ting, PhD
Kiji Therapeutics
Cleveland, United States

Hideto Yamaguchi, PhD
Astellas Pharma Inc.
Tsukuba, Japan

Xiaokui Zhang, PhD
Aspen Neuroscience
San Diego, Unites States

Daisuke Sugiyama, MD, PhD
Hiroshima University
Fukuoka, Japan